Bovie Medical Corporation Provides Update on Recent Developments for J-Plasma
Jan 12 15
Bovie Medical Corporation provided an update on recent developments for J-Plasma. The company announced that all J-Plasma disposable hand pieces as well as the Bovie Ultimate generator have received CE Mark approval for compliance with European Union safety, health and environmental protection requirements. As a result, the company will be able to sell these devices in the 31 countries of the European Economic Area.
Bovie Seeks Acquisitions
Dec 17 14
Bovie Medical Corporation (AMEX:BVX) is looking for acquisition opportunities. Bovie has filed a shelf registration of $25 million. Bovie stated, “We currently intend to use the net proceeds from the sale of securities offered by this prospectus for the continued development and marketing of our J-Plasma® technology and for working capital and other general corporate purposes, including capital expenditures, facilities expansion, acquisitions of complementary products, technologies or businesses and repaying indebtedness we may incur from time to time.”
Bovie Medical Receives FDA 510(k) Approval for Bovie Ultimate Generator
Dec 16 14
The Bovie Ultimate is a high frequency electrosurgical generator that can be used for delivery of RF energy and/or helium gas plasma to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The generator offers users monopolar, bipolar and plasma features, including one J-Plasma helium gas outlet, in a single generator. Its pad-sensing system reduces the risk of patient burns, but this feature is not required when using helium gas mode for soft tissue coagulation. The Bovie Ultimateâ„¢ will replace Bovie's ICON GS plasma system. The Company expects commercial launch of the new product in February, 2015.
Bovie Medical Corporation Presents at LD Micro Conference, Dec-03-2014 09:00 AM
Nov 18 14
Bovie Medical Corporation Presents at LD Micro Conference, Dec-03-2014 09:00 AM. Venue: Luxe Sunset Boulevard Hotel, 11461 Sunset Boulevard, Los Angeles, California, United States. Speakers: Robert L. Gershon, Chief Executive Officer and Director.
Bovie Medical Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
Nov 6 14
Bovie Medical Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company's sales were $6,788,000 compared to $5,794,000 a year ago. Loss from operations was $2,367,000 compared to $475,000 a year ago. Loss before income taxes was $4,084,000 compared to $516,000 a year ago. Net loss was $2,734,000 compared to $341,000 a year ago. Net loss attributable to common shareholders was $2,976,000 or $0.17 per basic and diluted share compared to $341,000 or $0.02 per basic and diluted share a year ago. Adjusted non-GAAP net loss was $465,000 or $0.04 per basic and diluted share compared to $352,000 or $0.02 per basic and diluted share a year ago.
For the nine months, the company's sales were $20,214,000 compared to $17,532,000 a year ago. Loss from operations was $4,056,000 compared to $2,790,000 a year ago. Loss before income taxes was $13,987,000 compared to $2,944,000 a year ago. Net loss was $12,092,000 compared to $1,870,000 a year ago. Net loss attributable to common shareholders was $12,760,000 or $0.72 per basic and diluted share compared to $1,870,000 or $0.11 per basic and diluted share a year ago. Adjusted non-GAAP net loss was $2,223,000 or $0.13 per basic and diluted share compared to $980,000 or $0.06 per basic and diluted share a year ago.